Healthcare News

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --  -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON,...

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for...

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three...

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

ADARx Pharmaceuticals receives FDA Fast Track Designation for Onvuzosiran, siRNA therapeutic candidate being developed for the treatment of HAE

- Former Deputy Director of the FDA’s Office of Neuroscience  - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the...

Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and...

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious...

PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

Cette autorisation repose sur des données de Phase 3 sans précédent, démontrant une amélioration statistiquement significative de la survie sans progression et de la survie globale par rapport aux...